[
    "0007.TIF\" file=\"https://surechembl.org/api/assets/attachment/215084088/US/20130101/B2/000008/34/40/04/US08344004-20130101-C00007.TIF\"/><img id=\"EMI-C00008\" path=\"US08344004-20130101-C00008.TIF\" file=\"https://surechembl.org/api/assets/attachment/215084172/US/20130101/B2/000008/34/40/04/US08344004-20130101-C00008.TIF\"/><img id=\"EMI-C00009\" path=\"US08344004-20130101-C00009.TIF\" file=\"https://surechembl.org/api/assets/attachment/215084174/US/20130101/B2/000008/34/40/04/US08344004-20130101-C00009.TIF\"/><img id=\"EMI-C00010\" path=\"US08344004-20130101-C00010.TIF\" file=\"https://surechembl.org/api/assets/attachment/215084129/US/20130101/B2/000008/34/40/04/US08344004-20130101-C00010.TIF\"/><img id=\"EMI-C00011\" path=\"US08344004-20130101-C00011.TIF\" file=\"https://surechembl.org/api/assets/attachment/215084036/US/20130101/B2/000008/34/40/04/US08344004-20130101-C00011.TIF\"/><img id=\"EMI-C00012\" path=\"US08344004-20130101-C00012.TIF\" file=\"https://surechembl.org/api/assets/attachment/215084094/US/20130101/B2/000008/34/40/04/US08344004-20130101-C00012.TIF\"/><img id=\"EMI-C00013\" path=\"US08344004-20130101-C00013.TIF\" file=\"https://surechembl.org/api/assets/attachment/215084062/US/20130101/B2/000008/34/40/04/US08344004-20130101-C00013.TIF\"/><img id=\"EMI-C00014\" path=\"US08344004-20130101-C00014.TIF\" file=\"https://surechembl.org/api/assets/attachment/215084086/US/20130101/B2/000008/34/40/04/US08344004-20130101-C00014.TIF\"/></p>The activity of the compounds was tested as follows:</p>Determination of EC50 Values of PPAR Agonists in the Cellular PPARalpha Assay</p>Principle</p>The potency of substances which bind to human PPARalpha and activate it in an agonistic manner is analyzed using a stably transfected HEK cell line (HEK=human embryo kidney) which is referred to here as PPARalpha reporter cell line. It contains two genetic elements, a luciferase reporter element (pdeltaM-GAL4-Luc-Zeo) and a PPARalpha fusion protein (GR-GAL4-humanPPARalpha-LBD) which mediates expression of the luciferase reporter element depending on a PPARalpha ligand. The stably and constitutively expressed fusion protein GR-GAL4-humanPPARalpha-LBD binds in the cell nucleus of the PPARalpha reporter cell line via the GAL4 protein portion to the GAL4 DNA binding motifs 5\u2032-upstream of the luciferase reporter element which is stably integrated in the genome of the cell line. There is only weak expression of the luciferase reporter gene in the absence of a PPARalpha ligand if fatty acid-depleted fetal calf serum (cs-FCS) is used in the assay. PPARalpha ligands bind and activate the PPARalpha fusion protein and thereby stimulate the expression of the luciferase reporter gene. The luciferase which is formed can be detected by means of chemiluminescence via an appropriate substrate.</p>Construction of the PPARalpha Reporter Cell Line</p>The PPARalpha reporter cell line was prepared in two stages. Firstly, the luciferase reporter element was constructed and stably transfected into HEK cells. For this purpos",
    "ach plate is charged with a standard PPARgamma agonist, which is likewise diluted in 11 different concentrations, in order to demonstrate the functioning of the assay in each individual plate. The assay plates are incubated in an incubator at 37\u00b0 C. and 5% CO2.</p>Day 4</p>After removal of the medium by aspiration, 50 \u03bcl of Dual-Glo\u2122 reagent (Dual-Glo\u2122 Luciferase Assay System; Promega) are added to each well in accordance with the manufacturer's instructions in order to lyze the cells and provide the substrate for the firefly luciferase (Photinus pyralis) formed in the cells. After incubation at room temperature in the dark for 10 minutes, the firefly luciferase-mediated chemiluminescence is measured in a measuring instrument (measuring time/well 1 sec; Trilux from Wallac). Then 50 \u03bcl of the Dual-Glo\u2122 Stop &amp; Glo reagent (Dual-Glo\u2122 Luciferase Assay System; Promega) is added to each well in order to stop the activity of the firefly luciferase and provide the substrate for the Renilla luciferase expressed by the reference plasmid pRL-CMV. After incubation at room temperature in the dark for a further 10 minutes, a chemiluminescence mediated by the Renilla luciferase is again measured for 1 sec/well in the measuring instrument.</p>Evaluation</p>The crude data from the luminometer are transferred into a Microsoft Excel file. The firefly/Renilla luciferase activity ratio is determined for each measurement derived from one well of the microtiter plate. The dose-effect plots and EC50 values of PPAR agonists are calculated from the ratios by the XL.Fit program as specified by the manufacturer (IDBS).</p>PPARgamma EC50 values in the range from 1 nM to &gt;10 \u03bcM were measured for the PPAR agonists described in this application. Compounds of the invention of the formula I activate the PPARgamma receptor.</p>The examples given in Table I serve to illustrate the invention, but without limiting it.</p><img id=\"EMI-C00015\" path=\"US08344004-20130101-C00015.TIF\" file=\"https://surechembl.org/api/assets/attachment/215084176/US/20130101/B2/000008/34/40/04/US08344004-20130101-C00015.TIF\"/></p>TABLE IThe dotted line indicates the connection of the sulfonamide group.ExampleR1A\u20021\u2014CH(CH3)2<img id=\"EMI-C00016\" path=\"US08344004-20130101-C00016.TIF\" file=\"https://surechembl.org/api/assets/attachment/215084099/US/20130101/B2/000008/34/40/04/US08344004-20130101-C00016.TIF\"/> \u20022\u2014CH(CH3)2<img id=\"EMI-C00017\" path=\"US08344004-20130101-C00017.TIF\" file=\"https://surechembl.org/api/assets/attachment/215084060/US/20130101/B2/000008/34/40/04/US08344004-20130101-C00017.TIF\"/> \u20023\u2014CH(CH3)2<img id=\"EMI-C00018\" path=\"US08344004-20130101-C00018.TIF\" file=\"https://surechembl.org/api/assets/attachment/215084081/US/20130101/B2/000008/34/40/04/US08344004-20130101-C00018.TIF\"/> \u20024\u2014CH(CH3)2<img id=\"EMI-C00019\" path=\"US08344004-20130101-C00019.TIF\" file=\"https://surechembl.org/api/assets/attachment/215084147/US/20130101/B2/000008/34/40/04/US08344004-20130101-C00019.TIF\"/> \u20025\u2014CH(CH3)2<img id=\"EMI-C00020\" path=\"US08344004-20130101-C00020.TIF\" file=\"https://surechembl.org/api/assets/attachment/215084171/US/20130101/B2/000008/34/4",
    "> 11\u2014C6H5<img id=\"EMI-C00026\" path=\"US08344004-20130101-C00026.TIF\" file=\"https://surechembl.org/api/assets/attachment/215084119/US/20130101/B2/000008/34/40/04/US08344004-20130101-C00026.TIF\"/> 12\u2014Cyclohexyl<img id=\"EMI-C00027\" path=\"US08344004-20130101-C00027.TIF\" file=\"https://surechembl.org/api/assets/attachment/215084068/US/20130101/B2/000008/34/40/04/US08344004-20130101-C00027.TIF\"/> 13\u2014Cyclopropyl<img id=\"EMI-C00028\" path=\"US08344004-20130101-C00028.TIF\" file=\"https://surechembl.org/api/assets/attachment/215084148/US/20130101/B2/000008/34/40/04/US08344004-20130101-C00028.TIF\"/> 14\u2014CH(CH3)2<img id=\"EMI-C00029\" path=\"US08344004-20130101-C00029.TIF\" file=\"https://surechembl.org/api/assets/attachment/215084074/US/20130101/B2/000008/34/40/04/US08344004-20130101-C00029.TIF\"/> 15\u2014CH(CH3)2<img id=\"EMI-C00030\" path=\"US08344004-20130101-C00030.TIF\" file=\"https://surechembl.org/api/assets/attachment/215084191/US/20130101/B2/000008/34/40/04/US08344004-20130101-C00030.TIF\"/> 16\u2014CH(CH3)2 <img id=\"EMI-C00031\" path=\"US08344004-20130101-C00031.TIF\" file=\"https://surechembl.org/api/assets/attachment/215084046/US/20130101/B2/000008/34/40/04/US08344004-20130101-C00031.TIF\"/> 17\u2014CH(CH3)2<img id=\"EMI-C00032\" path=\"US08344004-20130101-C00032.TIF\" file=\"https://surechembl.org/api/assets/attachment/215084082/US/20130101/B2/000008/34/40/04/US08344004-20130101-C00032.TIF\"/></p>The potency of some of the described examples are indicated in the following table:</p>PPARdeltaPPARgammaExampleEC50 (\u03bcM)EC50 (\u03bcM)10.060.02620.0670.64730.0011.8040.220.9980.779&gt;10\nProcesses\n</p>The compounds of the general formula 1, where R1, R3, R4, R5, R6, and R7 are as defined above, according to the invention can be obtained as outlined to the reaction schemes below:</p><img id=\"EMI-C00033\" path=\"US08344004-20130101-C00033.TIF\" file=\"https://surechembl.org/api/assets/attachment/215084066/US/20130101/B2/000008/34/40/04/US08344004-20130101-C00033.TIF\"/></p>An amine of the general formula 2 is reacted with a compound of the formula 3, where X represents a halogen like F, Cl, Br, I, or an other leaving group, in an appropriate inert solvent at room temperature or at elevated temperature and in the presence of a base like triethylamine or potassium carbonate to afford the compound of the general formula 1.</p>Alternatively a sulphonylchloride of the general formula 4 is reacted with an amine of the general formula 5 in the presence of a base like triethylamine or pyridine and an inert solvent in the well known manner to yield the desired products of the formula 1. The intermediates 2 and 4 were prepared according to the following scheme:</p><img id=\"EMI-C00034\" path=\"US08344004-20130101-C00034.TIF\" file=\"https://surechembl.org/api/assets/attachment/215084122/US/20130101/B2/000008/34/40/04/US08344004-20130101-C00034.TIF\"/></p>An acetamide of the general formula 10 was reacted with chloro sulfonic acid to give the chlorosulfonyl derivative of the general formula 8, which, on reaction with the "
]